The addition of subcutaneous daratumumab to triplet therapy improved outcomes for certain patients with newly diagnosed ...

Johnson & Johnson’s pharmaceuticals unit said it had filed Darzalex Faspro (daratumumab+hyaluronidase), a subcutaneous formulation of the drug already approved in several blood cancers.

Johnson & Johnson has claimed FDA approval for new formulation of its blockbuster multiple myeloma drug Darzalex that cuts its dosing time to just a few minutes from hours and could help it fend ...

The deal will give Dr Reddy’s exclusive rights to commercialise subcutaneous and intravenous ... EU and CN sourced daratumumab. The company is now conducting comparative efficacy studies.

Daratumumab, hyaluronidase-fihj ... Hyaluronidase increases permeability of the subcutaneous tissue by depolymerizing hyaluronan, a polysaccharide found in the extracellular matrix.